Skip to content 
What is in the KLOW blend peptide formula?
The KLOW blend peptide combines GHK-Cu, BPC-157, TB-500 and KPV.1
| Ingredient | Listed amount | Mass share |
|---|---|---|
| GHK-Cu | 50 mg | 62.5% |
| BPC-157 | 10 mg | 12.5% |
| TB-500 | 10 mg | 12.5% |
| KPV | 10 mg | 12.5% |
| Total | 80 mg | 100% |
The amounts form a 5:1:1:1 ratio by mass, in the table’s ingredient order. This does not describe molecule counts or relative biological effects.
Understanding the four KLOW components
KLOW is a blend name. Its ingredients remain separate compounds, each with its own chemical identity and research literature.
GHK-Cu: the copper peptide component
GHK is a short peptide made from glycine, histidine and lysine; GHK-Cu is its copper complex. A laboratory study found increased collagen synthesis in fibroblast cultures exposed to GHK-Cu. Fibroblasts are cells involved in producing connective tissue. That work helps explain the ingredient’s connection with skin and tissue research.2
BPC-157: a 15-amino-acid peptide
BPC-157 is a peptide composed of 15 amino acids. Research using rat tendon tissue and cultured tendon cells examined cell movement, tissue outgrowth and survival under stress. The authors reported improvements in those experimental measurements.3
TB-500: the thymosin-related component
TB-500 appears in literature connected with thymosin beta-4. One analytical study identified a seven-amino-acid fragment, Ac-LKKTETQ, in the TB-500 preparation it examined.4 When reading related studies, check the material named in the methods: a fragment and full-length thymosin beta-4 are different molecules.
KPV: the lysine-proline-valine tripeptide
KPV takes its name from the one-letter codes for lysine, proline and valine. It is a tripeptide, meaning it contains three amino acids. Published work has investigated its uptake and inflammatory signaling in intestinal research models.5
For the studies behind these research areas, see KLOW peptide research: what the studies show. The KLOW vs GLOW comparison explains the formula difference and the added KPV.
How do mg, mcg and mg/mL differ?
The product listing describes KLOW as lyophilized, or freeze-dried, powder.1 Milligrams (mg) and micrograms (mcg or µg) measure mass; one milligram equals 1,000 micrograms.
Milligrams per milliliter (mg/mL) measure concentration in a liquid, which requires a specified final volume. Check whether a concentration refers to the complete blend or one named ingredient. The vial label alone does not establish an amount per administration or a schedule.
How does vial content differ from purity?
Content describes how much material is present. Purity describes an analytical result reported using a particular method and basis. Peptide reference-standard research evaluates these attributes separately, using characterized material to help determine the peptide content of a vial.6
For a batch certificate of analysis (COA), read the compound name, result, unit and method together. A result expressed in mg per vial answers a different question from a chromatographic purity percentage. Neither should be substituted for the other.
What can the ingredient studies tell us about the blend?
The cited studies examine individual ingredients using different materials and methods. Their findings explain the research interest in those components, but assessing the complete formula requires studies of that composition and a defined outcome. For a closer look at outcomes and their limitations, read KLOW peptide benefits.
Sources
Formula checked September 12, 2026. The supplier listing supports the stated composition; the scientific references support the ingredient descriptions and measurement distinctions.
- Pure Lab Peptides: KLOW 80 mg product listing.
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011.
- Esposito S, et al. Analytical identification and characterization of the thymosin beta-4 fragment in a TB-500 preparation. Drug Testing and Analysis. 2012.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
- McCarthy D, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharmaceutical Research. 2023.